Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $18.30 Average PT from Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have received an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $18.30.

A number of brokerages have weighed in on YMAB. HC Wainwright decreased their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Bank of America reduced their price target on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research note on Wednesday, March 5th. Finally, Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target on the stock.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. This represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $44,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter worth $46,000. ProShare Advisors LLC purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth $99,000. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics during the 3rd quarter valued at about $133,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after purchasing an additional 6,131 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Stock Up 1.6 %

Shares of YMAB stock opened at $4.50 on Wednesday. The stock has a market cap of $203.48 million, a PE ratio of -8.33 and a beta of 0.65. Y-mAbs Therapeutics has a 52-week low of $4.25 and a 52-week high of $17.78. The business has a 50-day simple moving average of $5.51 and a 200-day simple moving average of $9.34.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the prior year, the company posted ($0.02) EPS. Sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.